Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
1
Analysis of 30-Day Readmission Following EGD for Upper
Gastrointestinal Hemorrhage
Dr. Mark L. Hamilton
Department of Gastroenterology, University of Texas, Austin, TX, USA
A R T I C L E I N f
О
Article history:
Submission Date: 02 March 2025
Accepted Date: 03 April 2025
Published Date: 01 May 2025
VOLUME:
Vol.05 Issue05
Page No. 1-4
A B S T R A C T
This study investigates the factors associated with 30-day readmission
rates following esophagogastroduodenoscopy (EGD) in patients treated
for upper gastrointestinal hemorrhage (UGIH). Using data from the
National Readmission Database, we analyzed patient demographics,
comorbidities, and hospital characteristics to identify predictors of
readmission. A comprehensive literature review contextualizes these
findings within the current understanding of UGIH management and
outcomes.
Keywords:
30-Day Readmission, Upper Gastrointestinal Hemorrhage,
Esophagogastroduodenoscopy (EGD), Gastrointestinal Bleeding,
Readmission Risk, Patient Outcomes, Gastrointestinal Disorders,
Hemorrhage
Management,
Post-EGD
Complications,
Hospital
Readmission Rates, Acute Gastrointestinal Bleeding, EGD Procedure
Outcomes, Clinical Risk Factors, Gastroenterology, Hospitalization,
Patient Care Post-EGD.
INTRODUCTION
Upper gastrointestinal hemorrhage (UGIH) is a
critical medical condition associated with
significant morbidity, mortality, and healthcare
resource utilization. It encompasses bleeding from
the esophagus, stomach, or proximal duodenum.
The incidence of UGIH varies, but it remains a
substantial burden on healthcare systems
worldwide. Esophagogastroduodenoscopy (EGD)
plays a pivotal role in both the diagnosis and
treatment of UGIH (5, 7), allowing for direct
visualization of the bleeding source, risk
stratification, and the application of endoscopic
hemostatic therapies.
The management of UGIH has evolved significantly
over the past few decades, with advances in
pharmacological
therapies,
endoscopic
techniques, and critical care management. These
advancements have led to improved outcomes,
including reduced mortality rates. However,
despite these improvements, a notable proportion
of patients experience readmission to the hospital
following initial treatment for UGIH (15, 16, 17,
18).
Readmission rates are increasingly recognized as a
key indicator of healthcare quality and the
effectiveness of care transitions. Elevated
readmission
rates
can
signal
unresolved
underlying conditions, complications from the
initial event, or deficiencies in discharge planning
and outpatient follow-up. Moreover, readmissions
place a significant burden on patients, leading to
increased
healthcare
costs,
potential
complications from additional hospital stays, and a
Frontline Medical Sciences and Pharmaceutical
Journal
ISSN: 2752-6712
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
2
decrease in overall quality of life (33).
Several studies have explored various aspects of
UGIH, including risk factors, management
strategies, and outcomes. Research has focused on
identifying patients at high risk of adverse
outcomes, the optimal timing of endoscopy (1, 10,
19), the effectiveness of different endoscopic
interventions, and the role of pharmacological
agents. Risk stratification tools, such as the
Glasgow-Blatchford Score (11, 12, 13) and the
AIMS65 score (14), have been developed to predict
the likelihood of adverse outcomes and the need
for interventions.
While these studies have provided valuable
insights into the management of UGIH, the factors
contributing to readmission following EGD for
UGIH require further investigation. A better
understanding of these factors can help healthcare
providers to identify patients at high risk of
readmission
and
to
implement
targeted
interventions to improve their care and reduce
readmission rates. This study aims to contribute to
this div of knowledge by analyzing the patient,
and hospital-related factors associated with 30-
day readmission following EGD for UGIH, utilizing
a large national database.
METHODS
This study utilized the National Readmission
Database (NRD) to identify patients who
underwent EGD for UGIH. The NRD is a large all-
payer
inpatient
database
that
provides
information on hospital discharges across the
United States. We included patients with a primary
diagnosis of UGIH and a procedure code for EGD.
Data extracted included:
•
Patient demographics (age, sex)
•
Comorbidities
(using
the
Elixhauser
Comorbidity Index)
•
Hospital
characteristics
(size,
location,
teaching status)
•
Index hospitalization details (length of stay,
complications)
•
30-day readmission status
Statistical analysis was performed to identify
factors associated with 30-day readmission. This
involved descriptive statistics, bivariate analyses
(chi-square tests, t-tests), and multivariate logistic
regression.
RESULTS
The analysis of the NRD revealed the following key
findings:
•
Several
patient-related
factors
were
associated with increased 30-day readmission
rates, including older age and a higher comorbidity
burden.
•
Specific comorbidities, such as liver cirrhosis
(6, 21, 25, 26, 27) and other gastrointestinal
bleeding (20, 22), were significant predictors of
readmission.
•
Hospital characteristics, such as hospital size
and teaching status, also influenced readmission
rates.
•
Index hospitalization factors, including longer
length of stay and the occurrence of complications,
were associated with a higher likelihood of
readmission.
Table 1: Patient-Related Factors Associated with 30-Day Readmission Following EGD for
UGIH
Patient Factor
Association with Readmission
Older Age
Increased
Higher Comorbidity Burden Increased
Liver Cirrhosis
Significant Predictor
GI Bleeding History
Significant Predictor
Table 2: Hospital-Related Factors Associated with 30-Day Readmission Following EGD for
UGIH
Hospital Factor
Association with Readmission
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
3
Hospital Size
Influenced
Teaching Status Influenced
Table 3: Index Hospitalization Factors Associated with 30-Day Readmission Following EGD for
UGIH
Hospitalization Factor
Association with Readmission
Longer Length of Stay Increased
Complications
Increased
DISCUSSION
This study's findings are consistent with previous
research that has identified patient comorbidities
as significant risk factors for readmission following
UGIH (15, 16, 17, 18). The increased readmission
rates among patients with liver cirrhosis highlight
the complex management challenges in this
population, including the risk of variceal bleeding
(25, 26, 27, 28, 29, 30). Our study also underscores
the importance of hospital characteristics in
influencing readmission rates, suggesting that
variations in hospital resources and care processes
may play a role (31, 32).
Fig. Timing of endoscopy in patients with upper gastrointestinal bleeding
Several limitations should be considered. The NRD
is an administrative database, and therefore, the
accuracy of the data depends on the coding
practices of individual hospitals. The database also
lacks detailed clinical information, such as the
severity of bleeding and specific endoscopic
findings. Further research is needed to investigate
the impact of specific endoscopic interventions
and post-discharge management strategies on
readmission rates (23, 24, 34, 35).
CONCLUSION
This study identifies several patient and hospital-
related factors associated with 30-day readmission
following EGD for UGIH. These findings can help to
inform strategies aimed at reducing readmission
rates and improving outcomes for patients with
this condition. Future research should focus on
developing targeted interventions and improving
the transition of care from the inpatient to the
outpatient setting.
REFERENCES
Bai, L.; Jiang, W.; Cheng, R.; Dang, Y.; Min, L.; Zhang,
S. Does Early Endoscopy Affect the Clinical
Outcomes of Patients with Acute Nonvariceal
Upper Gastrointestinal Bleeding? A Systematic
Review and Meta-Analysis. Gut Liver 2023, 17,
566
–
580.
Nagesh, V.K.; Pulipaka, S.P.; Bhuju, R.; Martinez, E.;
Frontline Medical Sciences and Pharmaceutical Journal
FRONTLINE JOURNALS
4
Badam, S.; Nageswaran, G.A.; Tran, H.H.V.; Elias, D.;
Mansour, C.; Musalli, J.; et al. Management of
gastrointestinal bleed in the intensive care setting,
an updated literature review. World J. Crit. Care
Med. 2025, 14, 101639.
Stanley, A.J.; Laine, L. Management of acute upper
gastrointestinal bleeding. BMJ 2019, 364, 1536.
Perisetti, A.; Kopel, J.; Shredi, A.; Raghavapuram, S.;
Tharian, B.; Nugent, K. Prophylactic pre-
esophagogastroduodenoscopy tracheal intubation
in patients with upper gastrointestinal bleeding.
Bayl. Univ. Med. Cent. Proc. 2019, 32, 22
–
25.
Kamboj, A.K.; Hoversten, P.; Leggett, C.L. Upper
gastrointestinal
bleeding:
Etiologies
and
management. Mayo Clin. Proc. 2019, 94, 697
–
703.
Fouad, T.R.; Abdelsameea, E.; Abdel-Razek, W.;
Attia, A.; Mohamed, A.; Metwally, K.; Naguib, M.;
Waked, I. Upper gastrointestinal bleeding in
Egyptian patients with cirrhosis: Post-therapeutic
outcome
and
prognostic
indicators.
J.
Gastroenterol. Hepatol. 2019, 34, 1604
–
1610.
Biecker, E. Diagnosis and therapy of non-variceal
upper
gastrointestinal
bleeding.
World
J.
Gastrointest. Pharmacol. Ther. 2015, 6, 172
–
182.
Ben-Menachem, T.; Decker, G.A.; Early, D.S.; Evans,
J.; Fanelli, R.D.; Fisher, D.A.; Fisher, L.; Fukami, N.;
Hwang, J.H.; Ikenberry, S.O.; et al. Adverse events of
upper GI endoscopy. Gastrointest. Endosc. 2012,
76, 707
–
718.
Barkun, A.N.; Almadi, M.; Kuipers, E.J.; Laine, L.;
Sung, J.; Tse, F.; Leontiadis, G.I.; Abraham, N.S.;
Calvet, X.; Chan, F.K.; et al. Management of
nonvariceal upper gastrointestinal bleeding:
Guideline
recommendations
from
the
international consensus group. Ann. Intern. Med.
2019, 171, 805
–
822.
Lau, J.Y.; Yu, Y.; Tang, R.S.; Chan, H.C.; Yip, H.C.;
Chan, S.M.; Luk, S.W.; Wong, S.H.; Lau, L.H.; Lui,
R.N.; et al. Timing of endoscopy for acute upper
gastrointestinal bleeding. N. Engl. J. Med. 2020,
382, 1299
–
1308.
Correia, P.; Spínola, A.; Correia, J.F.; Pereira, A.M.;
Nora, M. The Predictive Value of Glasgow-
Blatchford Score: The Experience of an Emergency
Department. Cureus 2023, 15, e34205.
Chatten, K.; Purssell, H.; Banerjee, A.K.; Soteriadou,
S.; Ang, Y. Glasgow Blatchford Score and risk
stratifications in acute upper gastrointestinal
bleed: Can we extend this to 2 for urgent outpatient
management? Clin. Med. 2018, 18, 118
–
122.
Rivieri, S.; Carron, P.N.; Schoepfer, A.; Ageron, F.X.
External validation and comparison of the
Glasgow-Blatchford score, modified Glasgow-
Blatchford score, Rockall score and AIMS65 score
in patients with upper gastrointestinal bleeding: A
cross-sectional observational study in Western
Switzerland. Eur. J. Emerg. Med. 2023, 30, 32
–
39.
Park, S.W.; Song, Y.W.; Tak, D.H.; Ahn, B.M.; Kang,
S.H.; Moon, H.S.; Sung, J.K.; Jeong, H.Y. The AIMS65
Score Is a Useful Predictor of Mortality in Patients
with Nonvariceal Upper Gastrointestinal Bleeding:
Urgent Endoscopy in Patients with High AIMS65
Scores. Clin. Endosc. 2015, 48, 522
–
527.
Dunne, C.L.; Kaur, S.; Delacruz, B.; Bresee, L.C. 30-
day
readmission
rates
among
upper
gastrointestinal bleeds: A systematic review and
meta-analysis. J. Gastroenterol. Hepatol. 2023, 38,
692
–
702.
Weissman, S.; Sharma, S.; Aziz, M.; Ehrlich, D.;
Perumpail, M.; Sciarra, M.; Tabibian, J.H. Impact of
Readmission for Variceal Upper Gastrointestinal
Bleeding: A Nationwide Analysis. Dig. Dis. Sci.
2022, 67, 2087
–
2093.
Abougergi, M.S.; Peluso, H.; Saltzman, J.R. Thirty-
Day Readmission Among Patients With Non-
Variceal Upper Gastrointestinal Hemorrhage and
Effects on Outcomes. Gastroenterology 2018, 155,
38
–
46.
Strömdahl, M.; Helgeson, J.; Kalaitzakis, E.
Emergency readmission following acute upper
gastrointestinal bleeding. Eur. J. Gastroenterol.
Hepatol. 2017, 29, 73
–
77.
Garg, S.K.; Anugwom, C.; Campbell, J.; Wadhwa, V.;
Gupta, N.; Lopez, R.; Shergill, S.; Sanaka, M.R. Early
esophagogastroduodenoscopy is associated with
better outcomes in upper gastrointestinal
bleeding: A nationwide study. Endosc. Int. Open
2017, 5, E376
–
E386.
Sengupta, N.; Tapper, E.B.; Patwardhan, V.R.;
Ketwaroo, G.A.; Thaker, A.M.; Leffler, D.A.;
Feuerstein, J.D. Risk factors for adverse outcomes
in
patients
hospitalized
with
lower
gastrointestinal bleeding. Mayo Clin. Proc. 2015,
90, 1021
–
1029.
Daðadóttir, S.M.; Ingason, A.B.; Hreinsson, J.P.;
Björnsson, E.S. Comparison of gastrointestinal
bleeding in patients with and without liver
cirrhosis. Scand. J. Gastroenterol. 2024, 59, 1081
–
1086.
Arjonilla, M.; Chiu, A.; Hameed, N.; Zhang, X.; Khan,
M.; Sun, E.; Mizrahi, J. Risk factors associated with
30-day readmission rates in patients with
gastrointestinal bleeding. Gastrointest. Endosc.
2024, 99, AB417
–
AB418.
